# **TITLE:** Assessment of healthcare delivery in the early management of bacterial meningitis in UK young infants: An observational study

Address correspondence to: Dr Ifeanyichukwu O Okike

Clinical Research Fellow

Vaccine Institute & Institute for Infection and Immunity

St George's, University of London,

London SW17 0RE. United Kingdom

Tel: +44 (0)2087252788, Fax: +44 (0)2087250716

Email: iokike@sgul.ac.uk

#### Names and addresses of co-authors

Shamez N Ladhani, MD, PhD: Immunisation, Hepatitis and Blood Safety Department, Public

Health England, Colindale, London, & Institute for Infection and Immunity, St George's,

University of London, UK

Mark Anthony, MD, PhD: John Radcliffe Hospital, Oxford, UK

Nelly Ninis, MD: Paediatrics department, St. Mary's Hospital, Paddington. London, UK

Paul Heath, FRCPCH: Vaccine Institute & Institute for Infection and Immunity

St George's, University of London, UK

Word count: 3380

Keywords: bacterial, meningitis, young infants, healthcare delivery, assessment

# **ABSTRACT**

#### **OBJECTIVE:**

To define early presenting features of bacterial meningitis in young infants in England and to review the adequacy of individual case management as compared with relevant national guidelines and an expert panel review.

#### **DESIGN:**

Retrospective medical case note review and parental recall using standardised questionnaires.

#### **SETTING:**

England and Wales.

#### **PARTICIPANTS:**

Infants aged <90 days with bacterial meningitis diagnosed between July 2010 and July 2013.

#### **RESULTS:**

Of the 97 cases recruited across England and Wales, 66 (68%) were admitted from home and 31 (32%) were in hospital prior to disease onset. Almost all symptoms reported by parents appeared at the onset of the illness, with very few new symptoms appearing subsequently. Overall, 20/66 (30%) infants were assessed to have received inappropriate pre-hospital management. The median time from onset of first symptoms to first help was 5 hours (IQR: 2-12) and from triage to receipt of first antibiotic dose was 2.0 hours (IQR: 1.0-3.3) hours, significantly shorter in infants with fever or seizures at presentation compared to those without (1.7 [IQR, 1.0-3.0] vs. 4.2 [1.8-6.3] hours, p=0.02). Overall, 26 (39%) infants had a poor outcome in terms of death or neurological complication; seizures at presentation was the only significant independent risk factor (OR, 7.9; 95% CI: 2.3- 207.0). For cases in hospital already, the median time from onset to first dose of antibiotics was 2.6 (IQR: 1.3-

9.8) hours and 12/31 (39%) of infants had serious neurological sequelae at hospital discharge. Hearing test was not performed in 23% and, when performed delayed by  $\geq$ 4 weeks in 41%.

#### **CONCLUSIONS:**

In young infants, the non-specific features associated with bacterial meningitis appear to show no progression from onset to admission whereas there were small but significant differences in the proportion of infants with more specific symptoms at hospital admission compared with at the onset of the illness, highlighting the difficulties in early recognition by parents and healthcare professionals alike. A substantial proportion of infants received inappropriate pre- and post-hospital management. We propose a targeted campaign for education and harmonisation of practice with evidence-based management algorithms.

# STRENGTH AND LIMITATIONS

- The strength of this study lies in the detailed analysis of a large cohort of geographically representative young infants with bacterial meningitis; this is the first study of its kind in the United Kingdom.
- We did not find any significant differences between the recruited and non-recruited
  cases in relation to age, sex, region of the country and causal bacteria (data not
  shown).
- Because we relied on paediatricians using their discretion to contact parents, however,
   this may have led to exclusion of families of infants who died or developed severe
   sequelae where the paediatrician was reluctant to contact the family about the study.

- Conversely, some parents may have agreed to participate simply because they were concerned about their child's long-term outlook or about suboptimal healthcare.
- Another potential limitation is that we relied on parents' recall for onset and
  progression of early clinical features. There is, however, evidence from other serious
  infections such as meningococcal disease that parents are able to accurately recall in
  detail such life-changing events.

# **INTRODUCTION**

Bacterial meningitis in young infants remains a significant cause of mortality and long-term morbidity <sup>1</sup>. During 2010-11, we conducted national, prospective-population-based surveillance of bacterial meningitis in infants younger than three months of age in the United Kingdom and Ireland and found that 26% of 329 infants had poor outcomes at discharge<sup>2</sup>. Among survivors of neonatal meningitis in the 1980's, 50% had neurological sequelae at five years of age<sup>3</sup> and similar rates (40%) have been reported in survivors of neonatal bacterial meningitis in the 1990s<sup>4</sup>.

The pathogens responsible for bacterial meningitis in young infants are different to those causing meningitis in other age groups<sup>5</sup>, with group B streptococci (GBS) and *Escherichia coli* responsible for more than half the cases; neither are currently vaccine-preventable<sup>1</sup>.

It is recognised that the early presentations of meningitis in young infants can be subtle and non-specific. This poses a substantial challenge for parents and healthcare workers. In our national surveillance, for example, half the infants with bacterial meningitis did not have fever at presentation and only 5% had the classic triad of fever, bulging fontanelle and seizures<sup>2</sup>.

Studies of invasive meningococcal disease have been able to delineate the onset of specific symptoms and signs and chart their progression over the course of the illness<sup>6</sup>. This information has helped improve knowledge and increase awareness of meningococcal infections among parents and healthcare workers (http://www.meningitis.org/health-professionals/doctors-in-training). Early recognition of meningococcal infection coupled with rapid antibiotic treatment and more aggressive management of children with sepsis has subsequently led to improved outcomes<sup>7-9</sup>. In adults with sepsis, earlier antibiotics have been associated with higher survival rates<sup>10</sup>, but in infants the evidence base is poor even though they have the highest incidence of bacterial meningitis<sup>5</sup>.

We hypothesised that earlier recognition may lead to earlier healthcare interventions which in turn might improve the outcomes of bacterial meningitis in young infants. We, therefore, undertook a detailed assessment of the timing, course and progression of bacterial meningitis in young infants across England and Wales. We also compared their initial and subsequent clinical management with relevant national guidelines.

# **METHODS**

We undertook a detailed review of the clinical presentation and management of bacterial meningitis in young infants in England and Wales diagnosed between July 2010 and July 2013 from the perspectives of parents and healthcare workers. We aimed to recruit 100 eligible infants (**TABLE 1**)<sup>11-13</sup>. Cases were identified from LabBase2 (a national surveillance database used by National Health Service hospitals laboratories to voluntarily electronically report clinically significant infections to Public Health England)<sup>14</sup>..

Group	Definition			
Eligible infants	Infants <90 days of age in whom a bacterium was isolated			
	from the cerebrospinal fluid (CSF), or where a significant			
	bacterial pathogen was isolated from blood together with			
	CSF pleocytosis (defined as ≥20 cells / mm³ for infants 0-28			
	days of age and $\ge 10$ cells/ mm <sup>3</sup> for infants 29-89 days of age) <sup>11-13</sup>			
Age at diagnosis	Early onset (0-6 days) and late onset (7-89 days)			
Home admission	Infants admitted to hospital from home			
In-patients	Infants already in hospital at the time, either in the neonatal			
	unit, birthing centre or postnatal ward.			
Time from onset to first help	The time from when parents noticed the first clinical feature			
	to the time they sought any type of help (phone call or visit).			
Time from onset to first dose of antibiotics	The time from appearance of first clinical feature to first dose			
	of antibiotics.			
Time from triage to first dose of antibiotics	The time from when infant was triaged by a nurse to the time			
	of administration of the first dose of antibiotics.			
"In hours"	Triage in hospital between hours of 0900 and 1800.			
(www.hscic.gov.uk)				
Appropriateness	Advice given prior to admission was judged as appropriate or			
	inappropriate. Choice of empiric antibiotics and duration of			
	antibiotics were appropriate if in conformity with existing			
	guidelines. For example, the use of any antibiotics other than			
	amoxicillin and cefotaxime/ ceftriaxone in any infant			
	admitted from home would be classified as inappropriate.			

Table 1: Definitions

A study pack containing study details, a consent form and a questionnaire was sent to the local paediatrician to forward to parents. If families did not respond, we asked the paediatrician to send a second pack. Parents of all participants completed a questionnaire with

details about onset and progression of specific symptoms. Participating parents also gave informed written consent for the study investigators to access their infant's medical records. All stages of care, including pre-hospital management, initial hospital assessment, ongoing care and post-admission follow-up were assessed through an in-depth review of hospital notes.

# Assessment of management: Expert panel and national guidelines.

An expert panel consisting of a general paediatrician, neonatologist, paediatric infectious diseases consultant and a paediatric specialist registrar reviewed the data to determine appropriateness of pre-hospital management, delays in recognition, empiric antibiotics, antibiotic duration and follow-up. These were judged according to any national guidelines available at the time. The NICE feverish illness in children aged <5 years guideline <sup>15</sup> was used to assess the appropriateness of advice/actions prior to hospital admission in febrile infants; in the absence of fever, the expert panel proposed a standard best practice. The Bacterial Meningitis and Meningococcal Septicaemia in Children guideline <sup>16</sup> was used to assess the appropriateness of empiric antibiotics, length of treatment, and timing of audiology testing for all cases. The management of infants presenting in the first 72 hours of life was assessed against the NICE antibiotics for early onset neonatal infection guideline <sup>17</sup>. We adhered to the STROBE guidelines for reporting observational studies.

## **Data collection**

Parents completed a questionnaire, which recorded the time of first appearance and progression of pre-defined clinical features (online supplement on request). Information on

any illnesses in the previous two weeks was also requested. Hospital medical notes and GP letters in the medical notes were used to corroborate parental recollection of onset, timing and progression of events.

## **Data analysis**

The data are mainly descriptive. We plotted the appearance and course of symptoms from the time of onset of first symptoms. The timing of each subsequent feature was then recorded and rounded to the nearest hour. For children admitted from home, we calculated the number of hours from the onset of illness to seeking any medical help ("first help" = hospital attendance, GP attendance or phone contact with a health professional) and to hospital admission. We compared the prevalence of symptoms at onset and at hospital presentation (infants admitted from home) or at diagnosis (in-patients). We also compared presenting features and clinical management in infants admitted from home and in-patients. Continuous data that did not follow a normal distribution are described as medians with interquartile ranges (IQR) and compared using the Mann Whitney U or Kruskal Wallis test, as appropriate. Proportions were compared using chi-squared or Fisher's Exact Test, as appropriate. To identify independent risk factors for poor outcomes (death or serious complications), potential explanatory factors were included in a backward, stepwise multivariable logistic regression model and the least significant parameter was then sequentially removed until only those parameters with p <0.05 remained.

# RESULTS

A total of 224 infants with bacterial meningitis were identified and study information forwarded to the parents (**Figure 1**). The parents of 103 infants (46%) agreed to participate but six cases were subsequently excluded because they did not meet the inclusion criteria. Demographic data on parents and infants are shown in tables 2A and 2B. Cases were recruited from 48 hospitals representing all English regions (**TABLE 2B**). Sixty-six (68%) infant were at home when they became unwell and 31 (32%) were inpatients. Most parents (92/97, 95%) completed the study questionnaire. The median time (IQR) from diagnosis to return of questionnaire was 286 days (84-252).




Figure 1: Recruitment algorithm. (\*: died (8), moved away (5), foster care (2), language barrier (2)). Recruited cases were from 2010 (n=25), 2011 (n=39), 2012 (n=22) and 2013 (n=11)

Parameter	Mother	Father
Median parental age (IQR)	29 (26-33)	32 (26-36)
Parent's highest academic level: Mothers (n=79): fathers (n=77)		
Post graduate	16 (20%)	7 (9%)
Graduate	16 (20%)	15 (19%)
A levels	20 (25%)	13 (17%)
GCSEs	27 (34%)	42 (55%)
Parents accommodation: mothers (n=87); fathers (n=77)		
Own house/ flat	45 (52%)	45 (58%)
Rented house/ flat	35 (40%)	26 (34%)
Council house/ flat	7 (8%)	6 (8%)

Table 2A: Basic demographics of parents

# **CASES ADMITTED FROM HOME (n=66)**

The median age at diagnosis of bacterial meningitis was 14 days (IQR, 3-25), higher in cases admitted from home (17 [11-34] days) compared to cases already in hospital (1 [0-7]; p=0.0001). The most common features at onset of illness were poor feeding (n=44, 65%), lethargy (n=30, 45%) and fever (temperature  $\geq 38^{\circ}$ C) [n=30, 44%]. The majority of symptoms reported by parents appeared at the onset of infection (**Figure 2A**) and these symptoms persisted, with very few new symptoms appearing over the subsequent 24 hours (**Figure 2B**). However, there were small but significant differences in the proportion of infants with more specific symptoms at hospital admission compared with the onset of the illness: irritability (p=0.036), abnormal breathing (p=0.023), abnormal movement/ seizures (p=0.024) (Figure 2C).




Figure 2: 2A- Time (hours) at which parents first noticed a specific clinical feature. 2B-Number of features present at each hour as reported by parents. 2C- Clinical features present at onset and time of admission

Twenty parents (30%) took their infants straight to the hospital: the A&E department (n=15, 22.5%) or the urgent care centre (n=5, 7.5%). The other parents (n=46, 70%) sought help by phoning the GP (n=21, 32%), calling the 24-hour NHS direct telephone service (n=15, 23%), or contacting the community midwife (n=10, 15%); of these, 13 (28%) were advised to stay at home.

The median time from onset of first features to first help was 5.0 hours (IQR: 2.0-12.0). The

time to first help was not associated with early or late-onset disease, gestation at birth, presence of fever or seizure, region of the country, type of housing or level of maternal academic qualifications. The majority of parents (47/62, 76%) presented to hospital within 24 hours of onset of symptoms. 13 of 15 (93%) infants who presented after 24 hours had fever (n=8) or seizures (n=4) or both (n=1) at the time they presented to hospital. Eight of the 15 (53%) had attended their GP surgery before going to hospital, of these three were reviewed at the A&E/walk-in centre and sent home and two were initially seen by a community midwife (all five infants were seen <24 hours from onset). The remaining 7/15 (47%) infants were brought to hospital by their parents more than 24 hours from the onset of symptoms.

Overall, 20/66 (30%) infants were assessed to have received inappropriate pre-hospital management. Twelve infants with fever warranted further investigation according to the NICE guidelines and, in a further eight cases, there was a delay in seeking help despite the presence of worrying clinical features. Examples of inappropriate advice given to parents included being told that their child's fever was due to a change in milk formula, or to an umbilical hernia, or where prune juice was recommended for fever and irritability.

Male         52 (54%)           Term (≥37 weeks)         74 (76%)           Preterm (<37 weeks)         23 (24%)           32-36         14 (14%)           28-31         5 (5%)           <28         4 (4%)           BIRTH ORDER: Singleton         88 (91%)           Twins         9 (9%)           Age distribution: Early-onset: 0-6 days         30 (31%)           Late onset: 7-28 days         44 (45%)           29-89 days         23 (24%)           ROUTE OF ADMISSION: Home         66 (68%)           In-patient         31 (32%)           Ethnicity:         White         81 (84%)           Asian         6 (6%)           Black         4 (4%)           Unknown         6 (6%)           Region of England:         18 (19%)           Midlands and East of England         18 (19%)           London and integrated regions         13 (13%)           South of England         32 (38%)           Infants mode of feeding at diagnosis: Breastfeeding         32 (38%)           Mixed feeding         32 (38%)           BACTERIA:         Identified from CSF only         23 (24%)           Identified from CSF and blood         40 (41%)	Parameter	Value			
Preterm (<37 weeks)   23 (24%)   32-36   14 (14%)   25 (5%)   228   31   228   4 (4%)   4	Male	52 (54%)			
32-36	\ <u></u>				
28-31	Preterm (<37 weeks)				
Age distribution: Early-onset: 0-6 days	32-36	14 (14%)			
BIRTH ORDER: Singleton Twins   9 (9%)	28-31	5 (5%)			
Twins  Age distribution: Early-onset: 0-6 days	<28	4 (4%)			
Age distribution: Early-onset: 0-6 days	BIRTH ORDER: Singleton	88 (91%)			
Late onset : 7-28 days	Twins	9 (9%)			
29-89 days   23 (24%)	Age distribution: Early-onset: 0-6 days	30 (31%)			
ROUTE OF ADMISSION: Home	Late onset: 7-28 days	44 (45%)			
In-patient   31 (32%)	29-89 days	23 (24%)			
Ethnicity: White	ROUTE OF ADMISSION: Home	66 (68%)			
Asian   Black   Unknown   6 (6%)	In-patient	31 (32%)			
Black Unknown  Region of England: North of England Midlands and East of England London and integrated regions South of England Infants mode of feeding at diagnosis: Breastfeeding Mixed feeding Bottle	Ethnicity: White	81(84%)			
Unknown  Region of England: North of England Midlands and East of England London and integrated regions South of England Mixed feeding Bottle feeding Bottle feeding Bottle from CSF only Identified from CSF and blood Identified from blood only  GBS  E. coli Listeria monocytogenes Neisseria meningitidis Other Gram positive bacteria* **Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.  Alive	Asian	6 (6%)			
Region of England: North of England Midlands and East of England London and integrated regions South of England Infants mode of feeding at diagnosis: Breastfeeding Mixed feeding Bottle feeding Bottle feeding BACTERIA: Identified from CSF only Identified from CSF and blood Identified from blood only  GBS E. coli Listeria monocytogenes Neisseria meningitidis Other Gram positive bacteria* **Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1. **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.	Black	4 (4%)			
Midlands and East of England London and integrated regions South of England South of England Infants mode of feeding at diagnosis: Breastfeeding Mixed feeding Bottle feeding Bottle feeding BACTERIA: Identified from CSF only Identified from CSF and blood Identified from blood only Identified from blood only  GBS E. coli Listeria monocytogenes A (44%) Neisseria meningitidis Other Gram negative bacteria* Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1. **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.	Unknown	6 (6%)			
London and integrated regions South of England 39 (41%)  Infants mode of feeding at diagnosis: Breastfeeding Mixed feeding Bottle feeding 32 (38%) Bottle feeding 32 (33%)  BACTERIA: Identified from CSF only Identified from CSF and blood Identified from blood only 34 (35%)  GBS E. coli Listeria monocytogenes 4 (4%) Neisseria meningitidis Other Gram negative bacteria* Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1. **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.  Alive	Region of England: North of England	26 (26%)			
South of England  Infants mode of feeding at diagnosis: Breastfeeding Mixed feeding Bottle feeding Bottle feeding BACTERIA: Identified from CSF only Identified from CSF and blood Identified from blood only Identified from blood only  GBS E. coli Listeria monocytogenes Avisable Meisseria meningitidis Other Gram negative bacteria*  **Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.					
Infants mode of feeding at diagnosis: Breastfeeding  Mixed feeding  Bottle feeding  BACTERIA: Identified from CSF only Identified from CSF and blood Identified from blood only  GBS  E. coli Listeria monocytogenes Neisseria meningitidis Other Gram negative bacteria*  **Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.					
Mixed feeding Bottle feeding 32 (33%)  BACTERIA: Identified from CSF only Identified from CSF and blood Identified from blood only 34 (35%)  GBS E. coli Listeria monocytogenes 4 (4%) Neisseria meningitidis Other Gram negative bacteria* Neter Gram positive bacteria* *Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1. **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.	South of England				
Bottle feeding  BACTERIA: Identified from CSF only Identified from CSF and blood Identified from blood only  GBS  E. coli Listeria monocytogenes A (4%) Neisseria meningitidis Other Gram negative bacteria* Other Gram positive bacteria* *Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1. **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.	Infants mode of feeding at diagnosis: Breastfeeding				
BACTERIA: Identified from CSF only Identified from CSF and blood Identified from blood only  GBS  E. coli Listeria monocytogenes A (4%) Neisseria meningitidis Other Gram negative bacteria* Other Gram positive bacteria*  *Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.	Mixed feeding				
Identified from CSF and blood Identified from blood only  GBS  E. coli Listeria monocytogenes A (4%) Neisseria meningitidis Other Gram negative bacteria* Other Gram positive bacteria*  *Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.	Bottle feeding	32 (33%)			
Identified from blood only  GBS  E. coli  Listeria monocytogenes  Neisseria meningitidis  Other Gram negative bacteria*  Other Gram positive bacteria*  *Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.	BACTERIA: Identified from CSF only	23 (24%)			
GBS  E. coli  Listeria monocytogenes  Neisseria meningitidis  Other Gram negative bacteria*  Other Gram positive bacteria**  *Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.	Identified from CSF and blood	40 (41%)			
E. coli Listeria monocytogenes A (4%) Neisseria meningitidis Other Gram negative bacteria* Other Gram positive bacteria* *Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1. **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.  Alive	Identified from blood only	34 (35%)			
Listeria monocytogenes  Neisseria meningitidis  Other Gram negative bacteria*  Other Gram positive bacteria**  *Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.	GBS	65 (63%)			
Neisseria meningitidis4 (4%)Other Gram negative bacteria*10 (10%)Other Gram positive bacteria**5 (5%)*Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurellaspp. 1, Haemophilus influenzae 1.**Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.Alive96	E. coli				
Other Gram negative bacteria*  Other Gram positive bacteria**  *Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.	Listeria monocytogenes				
Other Gram positive bacteria**  *Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp. 1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.  Alive	Neisseria meningitidis				
*Pseudomonas spp. 3, Klebsiella spp. 2, Salmonella spp. 2, Citrobacter 1, Pasteurella spp.1, Haemophilus influenzae 1.  **Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.  Alive					
spp.1, Haemophilus influenzae 1.**Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.Alive96					
**Streptococcus pneumoniae 2, Streptococcus bovis 2 and α-haemolytic streptococcus 1.  Alive 96					
Alive 96	spp.1, Haemophilus influenzae 1.				
Alive 96					
Dead (after 28 hours in PICU after developing meningitis in the 4 <sup>th</sup> week of life).					
	Dead (after 28 hours in PICU after developing meningitis in the 4 <sup>th</sup> week of life).	1			

### A+E management

Around half of the infants (n=36, 55%) were triaged in A&E during normal working hours. The median time from triage to receipt of the first antibiotic dose was 2.0 hours (IQR: 1.0-3.3; > 1 hour in 43 infants, 73%), but was significantly shorter in infants with fever or seizures at presentation than those without these features (1.7 [IQR, 1.0-3.0] vs. 4.2 [1.8-6.3] hours, p=0.02). There was no significant difference in median time from triage to first antibiotic dose in infants, by early or late-onset disease, region of the country, time of day at presentation or whether a fluid bolus was given. The median time from onset to GP visit, hospital attendance and first dose of antibiotics varied by route taken before admission (Table 3). Onset to antibiotics time was significantly longer in those who were first seen by the GP.

Category	Onset to GP	Onset to hospital visit	Onset to first dose of antibiotics
Infants who went from	Not applicable	5.7 hours (2-8.4)	8 hours (4.8-13.5)
Home direct to hospital			
Infants who went from	10.5 hours (3-33)	11 hours (5.2-17)	13 hours (6.8-25)
Home to hospital via GP			
Infants who went to	9 hours (3.5-48)	52 hours (36-96)	57.5 hours (38-98.2)
hospital via GP, were			
sent home and went to			
hospital a second time			
P value	0.8	0.0001	0.0001

Table 3: Median time in hours (IQR) from onset to GP, hospital visit and first dose of antibiotics by route taken prior to hospital admission. (GP: General Practitioner).

Overall, 26 (39%) infants had a poor outcome in terms of death (one case) or neurological complication (25, 38%). These included motor disorder or developmental delay (n=12, 18%), seizures (n=7, 11%), hydrocephalus (n=5, 8%), hearing loss (n=5, 8%), cerebral infarct or ischaemia on MRI (n=3, 5%) or visual deficits (n=3, 5%). The median time in hours (IQR) from onset of illness to first help in infants with poor outcomes was longer than in those who

recovered without sequelae (6.25 [1-24] hours vs. 4.75 [2-10], p=0.8) but this was not statistically significant. The rate of poor outcome was also not statistically different between the 15 infants who presented to hospital >24 hours after onset of symptoms and those who presented <24hrs (8/15 [53%] vs. 18/47 [38%]; p=0.3). The interval between triage to first antibiotic dose was also not associated with poor outcome.

A number of pre-defined, potential explanatory factors (age, gender, time from onset to first help, delay in antibiotics, pre-hospital inappropriate advice, inappropriate empiric antibiotics, presence of fever, presence of seizures) were explored in univariate and multivariate analyses to identify risk factors for poor outcome; only the presence of seizures at presentation (OR, 7.9; 95% CI: 2.3- 207.0) was found to be an independent risk factor (supplement table 1).

### **In-patient infants (n=31)**

As with those infants presenting from home, parents of in-patient infants at the time of diagnosis reported that the majority of symptoms were all present at the onset of the illness (**Figure 3A**) and remained present until diagnosis, with only a few new symptoms appearing during the course of the illness (**Figure 3B**). The only significant difference between symptoms at onset and those at diagnosis was the proportion with breathing difficulty (p<0.001) (**Figure 3C**).




Figure 3: 3A- Time (hours) at which parents first noticed a specific clinical feature (in-patient cases). 3B- Number of features present at each hour as reported by parents (in-patient cases) 3C- Clinical features present at onset and time of admission (in-patient cases)

Two-thirds of infants (21/31, 68%) had onset of symptoms within 72 hours of birth and were, therefore, assessed against the NICE early-onset antibiotic guidelines. According to these guidelines, the maternal "red flags" (mainly chorioamnionitis/maternal sepsis in 5), baby "red flags" (respiratory distress after 4 hours of age in 9, shock in 4, seizures in 2 and need for ventilation at term in 1) or both, were present in 5/21 (24%), 15/21 (71%) and 17/21 (81%),

respectively. At the time of diagnosis 17/31 (55%) of these infants received a fluid bolus, 12/31 (39%) had seizures and 8/31 (26%) had a fever.

The median time from onset of symptoms to first antibiotic dose was 2.6 hours (IQR, 1.3-8.5), with 74% (23/31) receiving their first dose >1 hour after onset of symptoms and 4 infants (13%) receiving the first dose >24 hours after onset.

## **Outcomes among in-patient infants**

Overall, 12/31 (39%) of infants had a serious neurological complication at hospital discharge, including developmental delay or motor disorder (n=9, 29%), abnormal hearing (n=5, 16%), hydrocephalus/VP shunt (n=5, 16%), seizures (n=2, 6%) and abnormal MRI: cortical grey and white matter injury (n=1, 3%) and two infants were treated for cerebral abscesses. No significant risk factors for poor outcomes were identified in either the univariate or multivariate analyses (supplement table 1).

# Home vs. in-patient infants

The main differences between infants admitted from home and in-patient cases were age, presence of fever on presentation, timing of LP and time to discharge from outpatient follow-up (**Table 4**).

Variable	All cases	Home (n=66)	In-patient (n=31)	P value
Median age at disease (days)	14 (3-25)	17 (11-34)	1(0-7)	0.0001
Early onset (<7 days)	30 (31%)	8(12%)	22(71%)	< 0.0001
Male	52(54%)	34(52%)	18(58%)	0.5
Prematurity	23(24%)	8(12%)	15(48%)	< 0.0001
Out-of- hours presentation	47(48%)	30(45%)	17(55%)	0.4
Fever on presentation	48(51%)	40(61%)	8(26%)	0.001
Seizure at presentation	33 (34%)	21(32%)	12(39%)	0.5
Received fluid bolus at presentation	53(55%)	36(55%)	17(55%)	0.7
Antibiotics delay (hours)	2 (1.3-4)	2 (1-3.3)	2.6 (1.3-9.8)	0.09
LP done post first dose of antibiotics	57 (59%)	30 (45%)	27 (87%)	< 0.0001
Antibiotics to LP time>24 hours	33 (59%)	14 (47%)	19 (70%)	0.07
Median time to LP and no bacteria in CSF (hours)	46 (24-92.5)	24 (15.2-52.8)	65 (44-100.8)	0.017
Median time to LP and bacteria in CSF (hours)	7.3 (1.5-2.4)	3 (1-24)	9.5 (2-24)	0.3
Empiric antibiotics not in conformity with national guidelines	52 (54%)	35(53%)	17 (55%)	0.9
Discharge to first OPD review (months)	2.5 (2.0-3.5)	2.5 (2.0-4.0)	2.5 (2.0-2.5)	0.6
Discharge from follow up age <12 months	13 (14%)	12/65 (18%)	1/31 (3%)	0.03
Discharge from follow up age <24 months	31 (32%)	26/65 (40%)	5/31 (16%)	0.02
Hearing test performed in survivors*	74 (77%)	53/65 (82%)	21/31 (68%)	0.1
Neurological complications	40 (42%)	26/65 (40%)	14/31(45%)	0.6
Discharge to audiology test (days)	25(0-32)	24 (10-42)	26 (0-28)	0.2
Informed of meningitis support charities	12/97 (13)	11/66(17%)	2/31(6)	0.2

Table 4. Comparison of infants admitted from home and infants in hospital at the time of diagnosis (EO: early onset, OPD, out-patient department, LP: Lumbar puncture). \* There were 22 survivors without report of hearing test. 12 (13%) had no record of hearing test at review, 5 (5%) were transferred to another hospital where data was not available and 4 (12%) had the review <1 month after discharge and 1 (1%) missed two appointments.

#### **Empiric antibiotics**

The empiric antibiotics used in 35/66 (53%) and 17/31 (55%) of infants admitted from home and in-patient cases respectively were not in conformity with the appropriate NICE guidelines (Supplement table 2).

# Follow-up and hearing tests after discharge

The median time to first out-patient follow-up was 2.5 months (IQR; 2-3.5) and was not different amongst infants admitted from home and in-patient cases (**Table 4**). However, infants from home were more likely to be discharged from follow-up before 2 years of age. A hearing test was performed in 74/96 (77%) survivors (Table 4). The median time from discharge to hearing test was 25 days (IQR: 0-32), with 30 (41%) and 14 (19%) infants having the hearing test  $\geq$ 4 and  $\geq$ 6 weeks after hospital discharge respectively.

# **Discussion**

This is the first study to assess in detail the course of the illness in young infants with bacterial meningitis and the early healthcare they receive. Parental reporting of the early features of bacterial meningitis is a unique aspect of this study. We have shown that in infants with bacterial meningitis most of the symptoms and signs as reported by parents are present from the onset of the illness and there is little progression, with no or few additional symptoms developing as the illness progresses. Notably, up to 40% of infants did not develop fever at any time during their illness. In keeping with previous studies, only seizures at presentation were significantly associated with a poor outcome<sup>2</sup>.

The course of bacterial meningitis in young infants appears to be different to that of children with meningococcal meningitis. With a similar study design, Thompson, Ninis and colleagues demonstrated that meningococcal disease progresses in a stereotypical manner in all children, with a prodromal phase, early sepsis phase and meningism only as a late feature<sup>6</sup>. In terms of the healthcare-seeking behaviour for those infants admitted from home, 70% of parents had sought medical help prior to A&E attendance. Of concern, a significant proportion had received inappropriate advice suggesting that further training of frontline healthcare staff in recognising serious illness in children is required<sup>18</sup>. On the other hand, many of the parents who presented to hospital more than 24 hours after the initial healthcare contact, are most likely because their child's condition deteriorated, thus highlighting the importance of providing appropriate safety-netting advice to parents if they are advised to return home.

On admission to hospital, the median time from triage to first antibiotic dose was 2 hours, lower than that recently reported for childhood septicaemia (3 hours)<sup>19</sup> but higher than the recommended threshold of 1 hour<sup>20</sup>. We identified a number of reasons for this delay, including uncertainty in recognition (especially in those with non-specific presentations), over-reliance on the presence of fever, waiting for urine samples before giving antibiotics and waiting for handover between shifts. Presentation in-hours or out-of-hours did not influence time to first antibiotic, which is reassuring given that half of infant presented out of hours. That infants with fever or seizure received antibiotics more quickly than those without these features suggests that these delays can potentially be avoided. Miner et al showed that delay to antibiotics time is significantly shorter in patients who received it in the emergency department<sup>21</sup>. With appropriate education strategies, it is therefore possible to significantly improve antibiotic delivery time for infants<sup>22</sup>.

Most in-patient infants developed meningitis within 72 hours of birth, suggesting vertical transmission of infection. The recent NICE guidelines for early-onset antibiotics provides guidance on maternal, birth and infant risk factors that should lead to specific and timely antibiotic therapy<sup>17</sup>. Notably, 80% of infants had such risk factors, suggesting this to be a useful tool. However the time to antibiotic administration and choice of antibiotic was still very variable. Adult studies from USA and France reported low compliance to established guidelines<sup>23, 24</sup>.

There is still a need to reinforce to clinicians the importance of performing a timely hearing test in infants with bacterial meningitis. There is no record of such a test in 23% of cases and

even when done it was  $\geq$  4weeks in 40%. National guidelines emphasize the need for early diagnosis of deafness to allow early interventions such as cochlear implantation <sup>16</sup>. Follow-up of infants with bacterial meningitis is also believed to be important as it should allow early identification of those with neurodevelopmental impairment (likely to be around 50% of survivors)<sup>4, 25</sup> and timely intervention and support<sup>16</sup>.

# **Summary**

The impact of bacterial meningitis on young infants and their families is significant. Case fatality rates and severe complications among survivors remains unacceptably high, at least partly due to delayed recognition and management. Unlike children with meningococcal disease, for example, we were unable to identify any distinctive features at disease onset or of symptom progression that might aid earlier recognition or trigger earlier healthcare presentation. We propose a targeted campaign for education of new parents, primary care health workers (including telephone advice providers) and hospital doctors regarding the nonspecific features, the lack of progression of clinical features at least in the first 24 hours and the lack of fever in young infants with bacterial meningitis. There is also need to explore ways of harmonising clinical practice with evidence-based management algorithms, including timely investigation and administration of appropriate antibiotics and adequate follow up of infants with bacterial meningitis.

### **Ethical Approval**

Ethical approval was given by Cambridgeshire 2 REC (Ref: 10/H0308/64). Paediatricians were approached by email asking if there would be willing to take part in the study. If in agreement, a National Institute for Health Research Coordinated System for gaining NHS Permission (NIHR CSP) application was made and the hospital listed once approval was granted.

## **Competing interests**

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi\_disclosure.pdf and declare: no support from any organisation for the submitted work; PTH is a consultant to Novartis and Pfizer on group B streptococcus vaccines but receives no payment for this. NN is a consultant to Pfizer on Meningococcal Group B vaccines, has received honoraria to teaching on meningitis from Novartis. All other authors declare no conflicts of interests. The ICMJE Form for Disclosure of Potential conflicts of Interest has been submitted.

# **Funding statement**

The Meningitis Research Foundation funded the study, and initial data collection and analysis. The funding body did not influence study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit the paper for publication. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

#### **Contributorship statement:**

Ifeanyichukwu O Okike completed the ethics application form, finalised the data collection tool, coordinated the study, entered all data into an Access database, data interpretation, performed the analysis and wrote the initial manuscript, reviewed and revised the manuscript and submitted the final manuscript.

Shamez N Ladhani helped with case ascertainment from the Public Health England, supported the data analysis and data interpretation, reviewed and revised the manuscript and approved the final manuscript.

Mark Anthony co-conceived and designed the study including the grant application, was a member of the expert panel who reviewed the management of cases, took part in data interpretation, reviewed and revised the manuscript and approved the final manuscript. Nelly Ninis co-conceived and designed the study including the grant application, was a member of the expert panel who reviewed the management of cases, took part in data interpretation, reviewed and revised the manuscript and approved the final manuscript. Paul T Heath was the Chief Investigator, co-conceived and designed the study including the grant and ethics application, was a member of the expert panel who reviewed the management of cases, contributed to the data analysis and data interpretation, reviewed and revised the manuscript and approved the final manuscript.

#### Acknowledgement

We acknowledge the meningitis support charities (Meningitis Research

Foundation, Meningitis Now formerly Meningitis Trust and Meningitis UK) and the Group B Strep Support charity for their help with reports from parents. We are grateful to Prof Alan P Johnson who co-conceived and designed the study including the grant application, led the Labbase data collection at the Public Health England, his colleagues Katherine L Henderson, Ruth M Blackburn and Berit Muller-Pebody who coordinated the laboratory reporting via Labbase.

We also wish to acknowledge the local paediatricians who were participant identification centre (PIC) contacts.

# **Transparency declaration:**

The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained

### **Copyright/licence for publication**

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of

electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

**Data sharing:** We are happy to share our anonymised raw data which is not included in the manuscript. All requests should be made to the corresponding author.

## What this paper adds

Section 1: What is already known on this subject

- The incidence of bacteria meningitis is higher in young infants than in any other age
  group and is often associated with a poor outcome this has not changed over the last
  three decades
- The early clinical presentation of meningitis in young infants can be subtle and nonspecific

# Section 2: What this study adds

- The majority of symptoms and signs in young infants with bacterial meningitis are
  present at the onset of the illness, with little progression over time.
- Inadequate pre-hospital management, delayed antibiotic administration in hospital and post discharge management were found in a significant proportion of cases.

# ONLINE SUPPLEMENT

	A	All cases		Home (n=66)		In-patient (n=31)			
Parameter	No complications	Complications	P-value	No complications	Complications	P-value	No complications	Complications	P value
				(n=40)	(n=26)		(n=17)	(n=14)	
Median age at presentation	14 (3-31)	12 (3-23)	0.4	19 (13-37)	16 (9-25)	0.3	1 (0-3)	2 (1-8)	0.3
Early onset	16/57 (28)	14/40 (35)	0.5	3/40 (8)	5/26 (19)	0.2	13/17 (76)	9/14 (64)	0.7
Male	29 (51)	23/40 (58)	0.5	20/40 (50)	14/26 (54)	0.8	9/17 (53)	9/14 (64)	0.7
Prematurity	11/57 (19)	12/40 (30)	0.2	4/40 (10)	4/26 (15)	0.7	7/17 (41)	8/14 (57)	0.4
Median maternal age	30 (26-35)	29 (24-32)	0.2	29 (26-34)	29 (24-32)	0.8	31(27-40)	27(23-33)	0.07
OOH presentation	31/57 (54)	16/40 (40)	0.2	21/40 (53)	9/26 (35)	0.2	10/17 (59)	7/14 (50)	0.6
Inappropriate advice	NA	NA	NA	16/40 (40)	14/26 (54)	0.3	NA	NA	NA
Fever or seizure	39/57 (68)	32/40 (80)	0.2	30/40 (75)	24/26 (92)	0.1	9/17 (53)	8/14 (57)	0.8
Fever	30/ 57 (53)	18/40 (45)	0.5	25/40 (63)	15/26 (58)	0.7	5/17 (29)	3/14 (21)	0.7
Seizure	13/57 (23)	20/40 (50)	0.005	7/40 (18)	14/26 (54)	0.002	6/17 (35)	6/14 (43)	0.7
Fluid bolus	30/57 (53)	24/40 (60)	0.5	22/40 (55)	15/26 (58)	0.8	8/17 (47)	9/14 (64)	0.5
Bacteria in CSF	41/57 (72)	23/40 (58)	0.1	31/40 (78)	17/26 (65)	0.3	10/17 (59)	6/14 (43)	0.6
Non-conformity antibiotics	31/57 (54)	21/40 (53)	0.9	21/40 (53)	14/26 (54)	0.8	10/17 (59)	7/14 (50)	0.6
Antibiotics delay >6h	7/57 (12)	5/40 (13)	0.8	2/40 (5)	2/26 (8)	0.6	5/17 (29)	3/14 (21)	1.0
Onset to help ≥12h	NA	NA NA	NA	7/40 (18)	10/26(38)	0.06	NA 1 1 G 1 1	NA	NA

Supplementary Table 1: Univariate analysis of death (1 case) and serious complications. OOH= out of hours, h=hours, CSF= cerebrospinal fluid

Pathogen	HOME	IN-PATIENT
GBS:	Cefotaxime/ ceftriaxone alone 9	
Home (24)	Benzyl penicillin and gentamicin 7	Cefotaxime/ ceftriaxone alone 4
in-patient (10)	Amoxicillin and gentamicin 3	Benzyl penicillin and gentamicin 2
	Cefuroxime and metronidazole 1	flucloxacillin and gentamicin 2
	Cefotaxime and flucloxacillin 1	Amoxicillin and gentamicin 1
	Cefotaxime and gentamicin 1	Vancomycin and gentamicin 1
	Benzyl penicillin 1 and Co-amoxiclav 1	
E. coli (5)	Benzyl penicillin and gentamicin 4	Cefotaxime/ ceftriaxone 1
	Benzyl penicillin and cefotaxime 1	Tazocin and Vancomycin 1
N. meningitidis (3)	Cefotaxime/ ceftriaxone 3	
L. monocytogenes (2)	Cefotaxime 1	Cefotaxime 1
Pasteurella spp (1)	Benzyl penicillin and gentamicin 1	
Salmonella agama (1)	Flucloxacillin and gentamicin 1	
Klebsiella spp. (1)		Teicoplanin 1
S. bovis (1)		Cefotaxime 1
H. influenzae (1)		Cefotaxime and gentamicin 1

Supplementary Table 2: Isolated bacteria in cases where empiric antibiotics was not in conformity with existing guidelines and antibiotics started empirically

#### References

- 1. Okike IO, Johnson AP, Henderson KL, Blackburn RM, Muller-Pebody B, Ladhani SN, et al. Incidence, etiology, and outcome of bacterial meningitis in infants aged <90 days in the United kingdom and Republic of Ireland: prospective, enhanced, national population-based surveillance. *Clin Infect Dis* 2014;59(10):e150-7.
- 2. Okike IO, Ladhani SN, Johnson AP, Henderson KL, Blackburn RM, Muller-Pebody B, et al. Clinical characteristics and risk factors for poor outcomes in infants aged <90 days with bacterial meningitis in the United Kingdom and Ireland (submitted). *Arch Dis Child* 2016.
- 3. Bedford H, de Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Meningitis in infancy in England and Wales: follow up at age 5 years. *BMJ* 2001;323(7312):533-6.
- 4. de Louvois J, Halket S, Harvey D. Neonatal meningitis in England and Wales: sequelae at 5 years of age. *Eur J Pediatr* 2005;164(12):730-4.
- 5. Okike IO, Ribeiro S, Ramsay ME, Heath PT, Sharland M, Ladhani SN. Trends in bacterial, mycobacterial, and fungal meningitis in England and Wales 2004-11: an observational study. *Lancet Infect Dis* 2014;14(4):301-7.
- 6. Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, et al. Clinical recognition of meningococcal disease in children and adolescents. *Lancet* 2006;367(9508):397-403.
- 7. Booy R, Habibi P, Nadel S, de Munter C, Britto J, Morrison A, et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. *Arch Dis Child* 2001;85(5):386-90.
- 8. Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. *JAMA* 1991;266(9):1242-5.
- 9. Han YY, Carcillo JA, Dragotta MA, Bills DM, Watson RS, Westerman ME, et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. *Pediatrics* 2003;112(4):793-9.
- 10. Proulx N, Frechette D, Toye B, Chan J, Kravcik S. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. *QJM* 2005;98(4):291-8.
- 11. Garges HP, Moody MA, Cotten CM, Smith PB, Tiffany KF, Lenfestey R, et al. Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? *Pediatrics* 2006;117(4):1094-100.
- 12. Kestenbaum LA, Ebberson J, Zorc JJ, Hodinka RL, Shah SS. Defining cerebrospinal fluid white blood cell count reference values in neonates and young infants. *Pediatrics* 2010;125(2):257-64.
- 13. Greenberg RG, Smith PB, Cotten CM, Moody MA, Clark RH, Benjamin DK, Jr. Traumatic lumbar punctures in neonates: test performance of the cerebrospinal fluid white blood cell count. *Pediatr Infect Dis J* 2008;27(12):1047-51.

- 14. Pearson A, Chronias A, Murray M. Voluntary and mandatory surveillance for methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) bacteraemia in England. *J Antimicrob Chemother* 2009;64 Suppl 1:i11-7.
- 15. NICE. Feverish illness in children: assessment and initial management in children younger than 5 years.

  <a href="http://guidance.nice.org.uk/CG47/QuickRefGuide/pdf/English">http://guidance.nice.org.uk/CG47/QuickRefGuide/pdf/English</a>. (accessed 06 Sep 2016).</a>
- 16. NICE. Bacterial meningitis and meningococcal septicaemia: Management of bacterial meningitis and meningococcal septicaemia in children and young people younger than 16 years in primary and secondary care. http://guidance.nice.org.uk/CG102. (accessed 6 Sep 2016).
- 17. NICE. Neonatal infection (early onset): antibiotics for prevention and treatment. https://www.nice.org.uk/guidance/CG149. (accessed 06 Sep 2016).
- 18. Pearson GA e. Why Children Die: A Pilot Study 2006; England (South West,

North East and West Midlands), Wales and Northern Ireland. London: Confidential

Enquiry into Maternal and Child Health (CEMACH), 2008.

- 19. Irwin AD, Drew RJ, Marshall P, Nguyen K, Hoyle E, Macfarlane KA, et al. Etiology of childhood bacteremia and timely antibiotics administration in the emergency department. *Pediatrics* 2015;135(4):635-42.
- 20. Chaudhuri A, Martinez-Martin P, Kennedy PG, Andrew Seaton R, Portegies P, Bojar M, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. *Eur J Neurol* 2008;15(7):649-59.
- 21. Miner JR, Heegaard W, Mapes A, Biros M. Presentation, time to antibiotics, and mortality of patients with bacterial meningitis at an urban county medical center. *J Emerg Med* 2001;21(4):387-92.
- 22. Bissinger RL, Mueller M, Cox TH, Cahill J, Garner SS, Irving M, et al. Antibiotic timing in neonates with suspected hospital-acquired infections. *Adv Neonatal Care* 2013;13(1):22-8; quiz 29-30.
- 23. Chia D, Yavari Y, Kirsanov E, Aronin SI, Sadigh M. Adherence to standard of care in the diagnosis and treatment of suspected bacterial meningitis. *Am J Med Qual* 2015;30(6):539-42.
- 24. Georges H, Chiche A, Alfandari S, Devos P, Boussekey N, Leroy O. Adult community-acquired bacterial meningitis requiring ICU admission: epidemiological data, prognosis factors and adherence to IDSA guidelines. *Eur J Clin Microbiol Infect Dis* 2009;28(11):1317-25.
- 25. Stevens JP, Eames M, Kent A, Halket S, Holt D, Harvey D. Long term outcome of neonatal meningitis. *Arch Dis Child Fetal Neonatal Ed* 2003;88(3):F179-84.